SCHEMBL2240248

SCHEMBL2240248

BrCCN(Cc1ccccc1)Cc1ccccc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 1/20 0.50
ALDH1A1 P00352 3/20 0.48
TSHR P16473 2/20 0.48
TRPA1 O75762 1/20 0.48
HDAC3 O15379 2/20 0.46
HDAC1 Q13547 2/20 0.46
HDAC2 Q92769 2/20 0.46
HDAC8 Q9BY41 2/20 0.46
NCOR2 Q9Y618 2/20 0.46
HTT P42858 1/20 0.46
CNR2 P34972 1/20 0.45
TRPM8 Q7Z2W7 1/20 0.44
TRPV1 Q8NER1 1/20 0.44
AOC3 Q16853 1/20 0.44
OPRM1 P35372 2/20 0.44
OPRD1 P41143 2/20 0.44
OPRK1 P41145 2/20 0.44
CARM1 Q86X55 1/20 0.43
PRMT6 Q96LA8 1/20 0.43
PRMT8 Q9NR22 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Bromide SCHEMBL10680860 0.98 TDP1 (0.48) TDP1ALDH1A1TSHRTRPA1HDAC3
SCHEMBL537951 0.95 TDP1 (0.50) TDP1ALDH1A1TSHRTRPA1HDAC3
Bromide SCHEMBL29414651 0.93 TDP1 (0.48) TDP1ALDH1A1TSHRTRPA1HDAC3
SCHEMBL4081568 0.87 HTT (0.55) ALDH1A1TSHRTRPA1HDAC3HDAC1
SCHEMBL11690052 0.87 MAOB (0.54) ALDH1A1TSHRCNR2OPRM1
SCHEMBL3634860 0.86 HDAC3 (0.51) TDP1ALDH1A1TSHRTRPA1HDAC3
SCHEMBL9329761 0.84 HTT (0.53) ALDH1A1TSHRTRPA1HDAC3HDAC1
SCHEMBL19326604 0.84 HTT (0.53) ALDH1A1TSHRTRPA1HDAC3HDAC1
SCHEMBL11795941 0.82 HDAC3 (0.56) ALDH1A1TSHRHDAC3HDAC1HDAC2
SCHEMBL4974601 0.82 HDAC3 (0.61) ALDH1A1TSHRHDAC3HDAC1HDAC2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2026098529-A1 KINESIN KIF18A INHIBITORS AND USE THEREOF SHANGHAI APEIRON THERAPEUTICS COMPANY LIMITED (CN) 2026-05-15 WO disclosed
US-9463262-B2 Cell adhesive material for biological tissue SANYO CHEMICAL INDUSTRIES, LTD. (JP) 2016-10-11 US disclosed
US-8658639-B2 N-substituted-cyclic amino derivative DAINIPPON SUMITOMO PHARMA CO., LTD (JP) 2014-02-25 US disclosed
US-8658639-B2 N-substituted-cyclic amino derivative DAINIPPON SUMITOMO PHARMA CO., LTD (JP) 2014-02-25 US disclosed
US-20130289254-A1 CELL ADHESIVE MATERIAL FOR BIOLOGICAL TISSUE SANYO CHEMICAL INDUSTRIES, LTD. (JP) 2013-10-31 US disclosed
EP-2636415-A1 CELL ADHESIVE MATERIAL FOR BIOLOGICAL TISSUE Sanyo Chemical Industries, Ltd. (JP) 2013-09-11 EP disclosed
US-8389511-B2 Bicyclic heterocyclic derivative DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2013-03-05 US disclosed
US-8389511-B2 Bicyclic heterocyclic derivative DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2013-03-05 US disclosed
US-8389511-B2 Bicyclic heterocyclic derivative DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2013-03-05 US disclosed
US-20120122773-A1 N-SUBSTITUTED-CYCLIC AMINO DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2012-05-17 US disclosed
EP-2155676-A2 COMPOUNDS WITH ANTIPARASITIC ACTIVITY, APPLICATIONS THEREOF TO THE TREATMENT OF INFECTIOUS DISEASES CAUSED BY APICOMPLEXANS Commissariat à l'Energie Atomique (FR) 2010-02-24 EP disclosed
WO-2008146172-A2 COMPOUNDS WITH ANTIPARASITIC ACTIVITY, APPLICATIONS THEREOF TO THE TREATMENT OF INFECTIOUS DISEASES CAUSED BY APICOMPLEXANS COMMISSARIAT A L'ENERGIE ATOMIQUE (FR) 2008-12-04 WO disclosed
EP-1997805-A1 Compounds with antiparasitic activity, applications thereof to the treatment of infectious diseases caused by apicomplexans Commissariat à l'Energie Atomique (FR) 2008-12-03 EP disclosed
EP-1404691-B1 METHOD FOR PRODUCING PERACYLATED 1-O-GLYCOSIDES SCHERING AG (DE) 2005-03-09 EP disclosed
US-6831164-B2 Generation of peracylated 1-O-glycosides; obtain chemical intermediate, react with alkylating agent, heat and recover product SCHERING AKTIENGESELLSCHAFT (DE) 2004-12-14 US disclosed
EP-1404691-A2 METHOD FOR PRODUCING PERACYLATED 1-O-GLYCOSIDES SCHERING AKTIENGESELLSCHAFT (DE) 2004-04-07 EP disclosed
US-20030069402-A1 Process for the production of peracylated 1-0-glycosides SCHERING AG (DE) 2003-04-10 US disclosed
WO-2003006474-A2 METHOD FOR PRODUCING PERACYLATED 1-O-GLYCOSIDES SCHERING AKTIENGESELLSCHAFT (DE) 2003-01-23 WO disclosed
WO-2000058266-A1 DIVERGENT METHOD FOR THE SYNTHESIS OF DIETHYLENE TRIAMINEPENTA ACETICACID ESTERS MALLINCKRODT INC. (US) 2000-10-05 WO disclosed
EP-0970954-A1 3-PIPERIDYL-4-OXOQUINAZOLINE DERIVATIVES AND MEDICINCAL COMPOSITIONS CONTAINING THE SAME JAPAN TOBACCO INC. (JP) 2000-01-12 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030069402-A1 Process for the production of peracylated 1-0-glycosides B3GNT2, UGT8, UGGT1 TDP1 3195/4885ALDH1A1 723/4885TSHR 2450/4885
US-20120122773-A1 N-SUBSTITUTED-CYCLIC AMINO DERIVATIVE REN, AGTR1, AGTR2 TDP1 4428/4885ALDH1A1 484/4885TSHR 1316/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.